News

Upcoming Investment Conferences Spotlight Foghorn Therapeutics

Upcoming Investment Conferences Spotlight Foghorn Therapeutics

Foghorn Therapeutics to Spotlight Innovations at Investor Conferences

Foghorn Therapeutics Inc. (NASDAQ: FHTX), a leading biotech company, is renowned for its groundbreaking work in the field of gene therapies aimed at addressing serious diseases through the innovative correction of abnormal gene expression. Situated in CAMBRIDGE, this clinical-stage company is set to participate in two vital investor conferences that will showcase its commitment to transforming healthcare.

Conferences Involved

Foghorn’s management team will be attending the B. Riley Securities Precision Oncology and Radiopharma Conference, as well as the TD Cowen 45th Annual Health Care Conference. These platforms offer a unique opportunity for Adrian Gottschalk, the President and Chief Executive Officer, to highlight Foghorn's advancements in oncology and beyond.

B. Riley Securities Precision Oncology and Radiopharma Conference

At the B. Riley Securities Conference, scheduled for February 28, 2025, at 9 a.m. EST in New York City, Foghorn will feature in a Synthetic Lethality Panel. This panel is significant as it focuses on innovative cancer therapies that exploit specific vulnerabilities within cancer cells, offering new hope for treatment methodologies.

TD Cowen 45th Annual Health Care Conference

Following the B. Riley event, Foghorn will present at the TD Cowen Health Care Conference on March 3, 2025, at 2:30 p.m. EST in Boston. This presentation will further delve into the company’s research and product pipeline, showcasing its potential impact on healthcare.

Virtual One-On-One Meetings and Other Opportunities

On March 3, Foghorn Therapeutics will also engage in virtual one-on-one meetings for interested investors. These meetings provide an excellent chance for stakeholders to gain insights into the company's strategic goals and future direction.

Accessing Presentation Webcast

For those unable to attend, a webcast of these presentations will be accessible through the Investor section of Foghorn Therapeutics' website. This interactive platform ensures that even remote investors can stay informed about Foghorn's latest developments and innovations.

About Foghorn Therapeutics

Foghorn Therapeutics is dedicated to discovering and developing a unique class of medicines that caters to genetically defined dependencies within the chromatin regulatory system. Utilizing their advanced Gene Traffic Control platform, the company methodically studies, identifies, and validates promising drug targets within this complex area of genetics. With a focus on oncology, Foghorn Therapeutics is building a robust pipeline of product candidates, aiming to provide transformative therapies to those in need.

Foghorn’s Mission and Research Focus

Foghorn’s mission is to revolutionize treatment approaches for serious diseases through advanced gene therapies. As the understanding of genetic factors in diseases continues to grow, Foghorn is at the forefront of research that integrates these insights into practical, transformative treatments. The company continues to emphasize its commitment to innovation and patient-centered care.

Stay Connected with Foghorn Therapeutics

To learn more about Foghorn Therapeutics and their pioneering work, interested individuals can explore the company’s website at www.foghorntx.com. For the latest updates, follow Foghorn on social media platforms like X (formerly Twitter) and LinkedIn, as they share insights on their research progress and innovations.

Contact Information

If you have any inquiries, please reach out to Karin Hellsvik at Foghorn Therapeutics Inc. via email at khellsvik@foghorntx.com.

Frequently Asked Questions

What is the focus of Foghorn Therapeutics?

Foghorn Therapeutics focuses on developing gene therapies that correct abnormal gene expression to treat serious diseases, primarily in oncology.

Which upcoming conferences will Foghorn participate in?

Foghorn will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference and the TD Cowen 45th Annual Health Care Conference.

Who will present at the conferences?

Adrian Gottschalk, the President and CEO of Foghorn, will be the key presenter at both conferences.

Can I access the presentations online?

Yes, the presentations will be available via webcast on Foghorn Therapeutics' Investor section of their website for those who cannot attend in person.

How can I contact Foghorn Therapeutics for more information?

You can contact Karin Hellsvik at Foghorn Therapeutics via email at khellsvik@foghorntx.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Photronics Faces Legal Heat: Key Investor Steps Now

Updated Category News Views 0

Eyes on Photronics: A Legal Quake Anytime you hear a stock price nosedive like a kamikaze just blew up its own runway, it ought to set off every investor's alarms. And if you’re tied into Photronics (NASDAQ:PLAB), buddy, it's time to catch up on what's driving this train off the rails. With a class period stretching from December 2025 through May 2026, the dish is a...

Continue Reading
Lyntris Advances KSAT Hyperion Satellite Program Milestone

Updated Category News Views 0

Lyntris and KSAT: A Technological Feat in Space Connectivity Well, if it ain't Lyntris back in the headlines again, pushing the envelope on space connectivity. If you're keeping tabs on the space tech space, there's a cracker of a development brewing. Lyntris Inc. (NYSE: LYNX) just checked off a crucial box in their playbook—the Critical Design Review, or CDR for those...

Continue Reading
Jim Morey Joins Pickleman's to Drive Expansion

Updated Category News Views 2

Jim Morey: Catalyst for Pickleman's Ambitious Dreams You ever heard of a sandwich joint ready to take on the big leagues? Because that's just what Pickleman's Gourmet Café is banking on with their latest move—tapping none other than Jim Morey for their executive advisory board. And let me tell ya, this ain't some run-of-the-mill hire. We're talking about a guy who's...

Continue Reading
Bucket List Wine Dinners Beckon to Los Angeles

Updated Category News Views 1

Sipping on the Extraordinary: LA Wine Soiree When was the last time you had a glass of wine that truly feels like you've unlocked a treasure chest? That's what LearnAboutWine.com is going for with their bucket list wine dinners in Los Angeles. Imagine tasting some of the world's most coveted bottles, all served with a level of polish that screams high-end dining. Led by...

Continue Reading
Perspecta's Study Reveals Troubling Data Accuracy Gaps

Updated Category News Views 1

Data Accuracy in Healthcare: A Persistent Problem Just when you think data's about numbers and cold, hard facts, healthcare jolts you awake. Perspecta's fresh insights onto provider data accuracy aren't just a snooze fest of statistics but a genuine wake-up call. This report peels open a can of worms some might prefer to ignore. With only half of provider data accurate,...

Continue Reading
FirstEnergy's Bold Move: Dormo Joins to Boost Power

Updated Category News Views 1

Changing the Game in Power Generation In the ever-shifting landscape of power generation, having a seasoned player at the helm can be the difference between stagnation and growth. FirstEnergy Corp. (NYSE:FE) has tapped Jon Dormo as its Vice President of Generation Project Development. The mission? Overhaul and expand projects to meet the increasing demands for...

Continue Reading
Pentair Faces Class Action Over Fraud Allegations

Updated Category News Views 1

Catastrophe Strikes Pentair Ah, the sweet sound of a lawsuit hammering down on Wall Street—a routine part of corporate life for some of the biggest players in the game. This time, the bell tolls for Pentair plc, and it ain't pretty, folks. News just dropped that investors in New York Stock Exchange: PNR are staring down a newly expanded securities fraud class action...

Continue Reading
McCann Systems Scores Big with Dual AV Awards Wins

Updated Category News Views 0

Piling Up the Accolades: McCann Systems Does It Again You know, getting industry awards can sometimes feel like counting beans, but when a company's snagging them year after year, that’s worth noting. McCann Systems is strutting its stuff with two Commercial Integrator Awards in 2026, cementing their reputation not just here in New Jersey, but across the AV industry....

Continue Reading
Money Market Funds Surge to Record $7.98 Trillion

Updated Category News Views 0

When Money Talks Fast: Market Funds Smash Records Picture this: money market funds have surged to an eye-watering $7.98 trillion. That's a lot of zeros, folks. And it's not just the usual humdrum growth; we're talking a hefty $44.75 billion increase in just one week, thanks to a cocktail of government funds and prime fund muscle, as the Investment Company Institute (ICI)...

Continue Reading
Weight Loss Drugs Linked to Genetic Hair Loss in Men

Updated Category News Views 1

When weight loss turns hairy, it's not just an old wives' tale. We have some solid evidence from those eggheads at NYU Langone Health, who unearthed this hairy connection between popular weight loss drugs and the glinting domes of the genetically predisposed. Understanding the Hair-Drug Connection The name Ozempic might sound familiar, and not just because it's been...

Continue Reading

Top 5 Most Recently Viewed Articles

Moroccan All Shares Experience Decline as Sectors Struggle

Updated Category News Views 64

The Effect of Declining Sectors on Moroccan Stocks Recent trading in Morocco reveals a slight downturn in the stock market, particularly impacting the Moroccan All Shares index, which has dipped by 0.53%. This decline is largely due to losses in several major sectors, notably beverage, real estate, and utilities. As the market evolves, investors are attentively watching...

Continue Reading
Bombardier Launches the Incredible Global 8000 Business Jet

Updated Category News Views 211

Introduction to the Global 8000 Business Jet The Global 8000 is the pinnacle of civil aviation, representing the fastest business jet ever produced. With a breathtaking top speed of Mach 0.95 and an impressive range of 8,000 nautical miles, this aircraft stands out as a revolutionary achievement in the realm of private aviation. It features the industry's lowest cabin...

Continue Reading
Exciting New Stock Option Granted by Taysha Gene Therapies

Updated Category News Views 145

Taysha Gene Therapies Grants Stock Option to New Employee DALLAS — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), an innovative biotechnology company focused on developing groundbreaking gene therapies for serious central nervous system disorders, has recently made news by granting a notable stock option. This strategic decision aims to attract and retain top talent...

Continue Reading
Engine Starter Fluid Market Growth Driven by Demand for Reliability

Updated Category News Views 108

Engine Starter Fluid Market Overview The engine starter fluid market is rapidly evolving, with a notable valuation of USD 362.8 million recorded in a recent report. This market is projected to grow significantly, reaching USD 450 million by the year 2025, representing an annual growth rate of 4.8%. Over the forecasted period from 2025 to 2035, the market is expected to...

Continue Reading
Japan's Approval of KOSTAIVE® Vaccine Marks COVID-19 Milestone

Updated Category News Views 167

Japan’s Health Ministry Approves KOSTAIVE® Vaccine In a significant step for public health, Japan's Ministry of Health, Labor and Welfare has approved the KOSTAIVE® vaccine from CSL and Arcturus Therapeutics. This cutting-edge self-amplifying mRNA COVID-19 vaccine is specifically aimed at battling the JN.1 strain of the Omicron variant. This approval underscores both...

Continue Reading